Institute for Medical Research and Occupational Health, HR-10001 Zagreb, Croatia.
University Hospital Centre Zagreb, HR-10000 Zagreb, Croatia.
Molecules. 2018 Jun 1;23(6):1332. doi: 10.3390/molecules23061332.
There is growing interest regarding the use of herbal preparations based on for medicinal purposes, despite the poorly understood interactions of their main constituent Δ⁸-tetrahydrocannabinol (THC) with conventional drugs, especially cytostatics. The objective of this pilot study was to prove whether the concomitant intake of THC impaired liver function in male Wistar rats treated with the anticancer drug irinotecan (IRI), and evaluate the toxic effects associated with this exposure. IRI was administered once intraperitoneally (at 100 mg/kg of the body weight (b.w.)), while THC was administered per os repeatedly for 1, 3, and 7 days (at 7 mg/kg b.w.). Functional liver impairments were studied using biochemical markers of liver function (aspartate aminotransferase-AST, alanine aminotransferase-ALP, alkaline phosphatase-AP, and bilirubin) in rats given a combined treatment, single IRI, single THC, and control groups. Using common oxidative stress biomarkers, along with measurement of primary DNA damage in hepatocytes, the degree of impairments caused at the cellular level was also evaluated. THC caused a time-dependent enhancement of acute toxicity in IRI-treated rats, which was confirmed by body and liver weight reduction. Although single THC affected ALP and AP levels more than single IRI, the levels of liver function markers measured after the administration of a combined treatment mostly did not significantly differ from control. Combined exposure led to increased oxidative stress responses in 3- and 7-day treatments, compared to single IRI. Single IRI caused the highest DNA damage at all timepoints. Continuous 7-day oral exposure to single THC caused an increased mean value of comet tail length compared to its shorter treatments. Concomitant intake of THC slightly affected the levels of IRI genotoxicity at all timepoints, but not in a consistent manner. Further studies are needed to prove our preliminary observations, clarify the underlying mechanisms behind IRI and THC interactions, and unambiguously confirm or reject the assumptions made herein.
对于基于大麻的草药制剂在医学上的用途,人们的兴趣日益浓厚,尽管其主要成分 Δ⁸-四氢大麻酚(THC)与常规药物(尤其是细胞抑制剂)的相互作用了解甚少。本初步研究的目的是证明在接受伊立替康(IRI)抗癌药物治疗的雄性 Wistar 大鼠中,同时摄入 THC 是否会损害肝功能,并评估与这种暴露相关的毒性作用。IRI 通过腹腔内单次给药(体重 100mg/kg),而 THC 通过口服重复给药 1、3 和 7 天(体重 7mg/kg)。在接受联合治疗、单一 IRI、单一 THC 和对照组的大鼠中,使用肝功能的生化标志物(天冬氨酸氨基转移酶-AST、丙氨酸氨基转移酶-ALP、碱性磷酸酶-AP 和胆红素)研究肝功能的损伤。通过测量肝细胞中初级 DNA 损伤,同时使用常见的氧化应激生物标志物,还评估了细胞水平引起的损伤程度。THC 导致接受 IRI 治疗的大鼠的急性毒性呈时间依赖性增强,这通过体重和肝脏重量的减轻得到了证实。尽管单一 THC 对 ALP 和 AP 水平的影响大于单一 IRI,但联合治疗后测量的肝功能标志物水平与对照组相比大多没有显著差异。与单一 IRI 相比,联合暴露在 3 天和 7 天的治疗中导致氧化应激反应增加。单一 IRI 在所有时间点都导致最高的 DNA 损伤。与较短的处理相比,连续 7 天口服暴露于单一 THC 导致彗星尾长的平均值增加。同时摄入 THC 略微影响了所有时间点 IRI 的遗传毒性水平,但不是以一致的方式。需要进一步的研究来证实我们的初步观察结果,阐明 IRI 和 THC 相互作用背后的潜在机制,并明确确认或否定本文中的假设。